HUTCHMED (China) Limited disclosed that 726,317 ordinary shares granted under its Long Term Incentive Plan (LTIP) on 5 June 2023 vested on 10 March 2026, following the company’s 2025 results announcement on 5 March 2026.

Chief Executive Officer and Chief Scientific Officer Dr Weiguo Su received 524,079 shares, equivalent to 0.52 million shares, while Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng received 202,238 shares, or 0.20 million shares. The awards vested at no cost to the executives and were conducted outside a trading venue, in line with the UK Market Abuse Regulation notification requirements.

The vesting forms part of HUTCHMED’s ongoing LTIP aimed at aligning senior management incentives with long-term shareholder interests. The company, dual-listed on Nasdaq, AIM and the Hong Kong Stock Exchange, focuses on developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases.

No other terms or financial considerations were disclosed in the filing.